FDA Approved: CYMBALTA — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for Cymbalta (duloxetine hydrochloride) from Eli Lilly, granting updated labeling under the NDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathic Pain
• Fibromyalgia
• Generalized Anxiety Disorder
• Major Depressive Disorder
• Musculoskeletal Pain

Drugs mentioned

• Cymbalta (duloxetine)

Snippet

SUPPL AP for CYMBALTA (DULOXETINE HYDROCHLORIDE)